Measles, mumps, and rubella (MMR) vaccine and heterologous immunity: a way out of the COVID-19 crisis?
Jahnavi Shrivastava, Manish Narang, Sunil Gomber.
Abstract
Heterologous immunity is a well-known concept in immunology wherein prior exposure to an antigen confers cross protection against an unrelated antigen. With the surge in global COVID-19 cases, there has been significant research into the application of vaccine induced heterologous immunity associated with measles, mumps, and rubella (MMR) vaccine, Bacillus Calmette–Guerin (BCG) vaccine, oral polio vaccine (OPV) and hepatitis A vaccine in curbing the worst outcomes of COVID-19 infection. Despite having specific vaccines against COVID-19, it is worthwhile exploring the application of available vaccines in the prevention of severe disease until the vaccines reach all sections of the population across the globe. In this article, we aim to outline the concept of heterologous immunity and its relevance in context to MMR vaccine and COVID-19.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
